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Alzheimer’s disease (AD) is characterized by enhanced -amyloid peptide (A) deposition along with glial activation in senile plaques,
selective neuronal loss, and cognitive deficits. Cannabinoids are neuroprotective agents against excitotoxicity in vitro and acute brain
damage in vivo. This backgroundprompted us to study the localization, expression, and function of cannabinoid receptors inADand the
possible protective role of cannabinoids after A treatment, both in vivo and in vitro. Here, we show that senile plaques in AD patients
express cannabinoid receptors CB1 and CB2 , together with markers of microglial activation, and that CB1-positive neurons, present in
high numbers in control cases, are greatly reduced in areas of microglial activation. In pharmacological experiments, we found that
G-protein coupling and CB1 receptor protein expression are markedly decreased in AD brains. Additionally, in AD brains, protein
nitration is increased, and, more specifically, CB1 and CB2 proteins show enhanced nitration. Intracerebroventricular administration of
the synthetic cannabinoid WIN55,212-2 to rats prevent A-induced microglial activation, cognitive impairment, and loss of neuronal
markers. Cannabinoids (HU-210, WIN55,212-2, and JWH-133) block A-induced activation of cultured microglial cells, as judged by
mitochondrial activity, cell morphology, and tumor necrosis factor- release; these effects are independent of the antioxidant action of
cannabinoid compounds and are also exerted by a CB2-selective agonist. Moreover, cannabinoids abrogate microglia-mediated neuro-
toxicity afterA addition to rat cortical cocultures. Our results indicate that cannabinoid receptors are important in the pathology of AD
and that cannabinoids succeed in preventing the neurodegenerative process occurring in the disease.
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Introduction
Alzheimer’s disease (AD), the most common form of dementia, is
characterized by the deposition of -amyloid peptide (A)
within one of its pathological hallmarks: the senile plaque. Acti-
vated microglia cluster at senile plaques (McGeer et al., 1987;
Dickson et al., 1988), and this seems to be responsible for the
ongoing inflammatory process in the disease. Transgenic mouse
models of AD also develop plaques in which A deposits and
activated microglia exist (Masliah et al., 1996; Frautschy et al.,
1998; Jantzen et al., 2002). Furthermore, microglial activation
results in neurodegeneration both in vitro (Meda et al., 1995; Gao
et al., 2002; Xie et al., 2002) and in vivo (Weldon et al., 1998;
Herrera et al., 2000; Iravani et al., 2002) paradigms. In this con-
text, recent studies have focused on the therapeutic interest of
limiting microglial activation and inflammation in AD and other
neurological disorders.
Cannabinoids, the active components of marijuana and their
analogs, exert a wide spectrum of central and peripheral effects by
activating specific cannabinoid receptors, two of which have been
well characterized to date: CB1 and CB2 (Howlett et al., 2002;
Piomelli, 2003). CB1 receptors are found in high density in the
nervous system (Herkenham et al., 1990), in which they mediate
cannabinoid psychoactivity, and all types of neural cells express
them. Thus, in addition to being present in neurons, CB1 recep-
tors exist in astrocytes (Bouaboula et al., 1995; Sa´nchez et al.,
1998), microglia (Waksman et al., 1999; Walter et al., 2003), and
oligodendrocytes (Molina-Holgado et al., 2002). In contrast, the
CB2 receptor is considered to be expressed solely in cells and
organs of the immune system and is unrelated to cannabinoid
psychoactivity. There are also recent reports on the existence of
CB2 receptors in microglia (Walter et al., 2003) and on cannabi-
noids affecting migration (Walter et al., 2003), as well as nitric
oxide (NO) and cytokine production (Waksman et al., 1999;
Puffenbarger et al., 2000; Facchinetti et al., 2003) in microglial
cell cultures in vitro.
Cannabinoids exert neuroprotection under different experi-
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mental conditions. Thus, cannabinoid receptor activation pro-
tects hippocampal or granule cerebellar neurons from excitotox-
icity (Skaper et al., 1996; Shen and Thayer, 1998; Hampson and
Grimaldi, 2001) and from hypoxia and glucose deprivation (Na-
gayama et al., 1999). In vivo, cannabinoids decrease hippocampal
neuronal loss and infarct volume after cerebral ischemia (Na-
gayama et al., 1999), acute brain trauma (Panikashvili et al.,
2001), and ouabain-induced excitotoxicity (van der Stelt et al.,
2001). These effects have been ascribed to inhibition of glutamate
transmission, reduction of calcium influx, and subsequent inhi-
bition of noxious cascades, such as tumor necrosis factor-
(TNF-) generation and oxidative stress.
This background prompted us to study the characteristics and
localization of cannabinoid receptors in AD brain, with particu-
lar emphasis on any relationship with microglial activation. Fur-
thermore, the effects of cannabinoid receptor activation were
studied in an animal model of AD in vivo and in a model of
A-induced microglial activation in vitro.
Materials andMethods
Materials. A25–35 and a peptide containing the same 11 amino acids but
with a scrambled (SCR) sequence (NeoMPS, Strasbourg, France) were
used throughout. A25–35 and the scrambled peptide were dissolved in
distilled water at a concentration of 2.5 mg/ml to allow self-aggregation
of the peptide and stored at 80°C until used. A1– 40 (NeoMPS) was
dissolved in PBS (1.72 mg/ml), aged at 37°C for 24 h (“fibrillar” peptide),
and was vortexed several times during that period, and aliquots were stored
at 80°C until used. The control (C) peptide was not subjected to aging
(“soluble” peptide). Aggregation of all of the peptides was confirmed by
microscopy after staining with Coomassie brilliant blue (Ferna´ndez-Tome´ et
al., 2004). WIN55,212-2 [R-()-(2,3-dihydro-5-methyl-3-[(4-morpholi-
nyl)methyl]1,2,3-de]-1,4-benzoxazin-6-yl)(1-naphthalenyl) methanone
sulfonate] was obtained from Sigma (St. Louis, MO), JWH-133
[(6aR,10aR),-3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro-6,6,9-tri-
methyl-6H-dibenzo[b,d]pyran] was a generous gift from Dr. J. W. Huffman
(Clemson University, Clemson, SC), HU-210 [(6aR,10aR)-3-(1,1-
dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-
dibenzo[b,d]pyran-9-methanol] was kindly given by Dr. R. Mechoulam
(The Hebrew University of Jerusalem, Jerusalem, Israel), AM251 [N-1-
(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-
pyrazole-3-carboxamide] was from Tocris Cookson (Bristol, UK), and
SR141716 [N-piperidino-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-
4-methyl-3-pyrazole carboxamide] and SR144528 [N-[(1S)-endo-
1,3,3-trimethyl bicyclo[2.2.1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-
1-(4-methylbenzyl)-pyrazole-3-carbo-xamide] were kindly donated by
Sanofi-Synthelabo (Montpellier, France). Each of these compounds was dis-
solved in DMSO at 10 mM concentration, and aliquots were stored at80°C,
with the exception of WIN55,212-2, which was initially dissolved in chloro-
form (on ice), quickly aliquoted to prevent evaporation, and dried under a
stream of N2, and aliquots were stored desiccated. Before their use, drugs
were diluted in the appropriate solvent (e.g., PBS or cell culture medium),
and DMSO never exceeded 0.1% in pharmacological or cell culture experi-
ments. Cell culture reagents were from Sigma unless otherwise stated. Salts
and other reactives were analytical grade from Merck (Darmstadt,
Germany).
Patient samples. For immunocytochemistry, cryoprotected and fixed
frozen samples from frontal cortex were obtained from the Neurologic
Tissue Bank (Hospital Clinic, Barcelona, Spain). Controls consisted of
three males and two females (mean SEM; 62.8 7.2 years of age; 9.5
2.2 h of postmortem interval), and clinically diagnosed and neuropatho-
logically defined AD patients consisted of three females and three males
(76.0  3.3 years of age; 12.5  3.1 h of postmortem interval). For
biochemical studies, frozen frontal cortex samples (control, n 18; AD,
n 18) were obtained from the London Brain Bank for Neurodegenera-
tive Diseases (Institute of Psychiatry, London, UK). Control subjects and
AD patients were matched for age (C, 71.8 2.6; AD, 77.4 2.2 years),
sex (13 females and 5 males per group), and postmortem delay (C, 38.7
4.7; AD, 33.3 5.3 h). Samples were maintained at80°C until assayed.
Immunocytochemistry. Immunostaining was performed on floating
sections (30m) as described previously (Go´mez del Pulgar et al., 2002).
For CB2 and N-Tyr immunostaining, antigen retrieval was achieved by
boiling sections in 1 mM EDTA, pH 8.0, for 5 min before the standard
labeling technique. Sections were incubated with the different antibodies
overnight at 4°C. Dilutions of antibodies were as follows: polyclonal
anti-CB1 (1:900; from Dr. K. Mackie, University of Washington, Seattle,
WA), polyclonal anti-CB2 (1:900; Affinity BioReagents, Golden, CO),
polyclonal anti-N-Tyr [1:000; Dr. J. Rodrigo, Cajal Institute, Consejo
Superior de Investigaciones Cientı´ficas (CSIC), Madrid, Spain] (Uttenthal et
al., 1998), monoclonal anti-GFAP (1:1000; Sigma), monoclonal anti-human
leukocyte antigen-D region related (HLA-DR) (1:15; MP Biomedicals,
Irvine, CA), and biotinylated tomato lectin (TL) (1:150; Sigma). Develop-
ment was conducted by the ABC method (Pierce, Rockford, IL), and immu-
noreactivity was visualized by 3,3-diaminobenzidine oxidation as chromo-
gen, with or without nickel enhancement.
Immunostaining of cell cultures, either neuronal or microglial, were
similarly performed after fixation with paraformaldehyde (4% in 0.1 M
phosphate buffer) for 30 min, followed by rinses with PBS. In addition,
rat microglia was immunostained with monoclonal anti-rat CD11
(OX42; 1:100; Serotec, Oxford, UK).
Omission of primary or secondary antibodies resulted in no immuno-
staining. Specificity of anti-CB1 and anti-CB2 staining was performed by
preabsorption of the antibodies with the antigenic peptides (kindly given
by Dr. K. Mackie), which completely abolished labeling.
3H-WIN55,212-2 and 35S-GTPS binding. 3H-WIN55,212-2 binding
was conducted as described previously (Breivogel et al., 2001). Briefly, P2
membrane fractions (80 g of protein) were incubated in assay buffer
(Tris 50 mM, pH 7.4, containing 3 mM MgCl2, 1 mM EDTA, and 1 mg/ml
fatty acid-free BSA) with 3 nM 3H-WIN55,212-2 (specific activity, 41.0
Ci/mmol; PerkinElmer Life Sciences, Boston, MA) at 30°C for 60 min.
Nonspecific binding was determined in the presence of 1 M SR141716.
Saturation curves were constructed with increasing concentrations of
3H-WIN55,212-2 (0.25–10 nM), and, in competition curves, several con-
centrations of the agonists or antagonists (1010 to 104 M) were as-
sayed. The binding was terminated by filtering through GF/C Whatman
(Maidstone, UK) filters (0.45m), incubated previously with 0.5% poly-
ethyleneimine for at least 2 h, using a Brandel (Gaithersburg, MD)
harvester, washed three times with ice-cold 5 mM Tris HCl, pH 7.4,
containing 1 mg/ml BSA, and the radioactivity was counted using an
LKB-Wallac (Gaithersburg, MD) scintillation counter. 35S-GTPS bind-
ing was performed as described previously (Breivogel et al., 2001). P2
membrane fractions (30 g of protein) were incubated in assay buffer
(50 mM Tris HCl, pH 7.4, containing 3 mM MgCl2, 100 mM Na Cl, 0.2 mM
EGTA, and 0.5 mg/ml fatty acid-free BSA) with 0.04 nM 35S-GTPS
(specific activity, 1250 Ci/mmol; PerkinElmer Life Sciences), 30 M
GDP, and 5 M WIN55,212-2 at 30°C for 60 min. Binding was termi-
nated by rapid filtration as above. Basal activity was determined in the
absence of agonist and nonspecific binding in the presence of 10 M of
unlabeled GTPS. Net stimulation was the difference of the binding in
the presence and in the absence (basal binding) of WIN55,212-2. Data
were expressed in femtomoles per milligram of protein. All of the proce-
dures for both assays were conducted in plasticware and dilutions of
radioligands and cold reagents in plastic tubes coated with 50 mM Tris
HCl, pH 7.4, containing 1 mg/ml BSA.
A and cannabinoid administration to rats.All of the experiments were
performed according to ethical regulations on the use and welfare of
experimental animals of the European Union and the Spanish Ministry
of Agriculture, and the procedures were approved by the bioethical com-
mittee of the CSIC.A administration to male Wistar rats was performed
essentially as described previously (Pavı´a et al., 2000). A25–35 or a pep-
tide with a scrambled sequence (NeoMPS), which was used as control,
were injected intracerebroventricularly daily for 7 d (20 g in 10 l of
saline per day), and the animals were tested at different times after the
first injection. Other animals received a cannabinoid (WIN55,212-2, 10
g in 10 l of 20% DMSO/80% saline per day) together with the pep-
tides. The Hamilton syringe used for intracerebroventricular injections
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was repeatedly washed with distilled water, followed by flushing with 1
mg/ml BSA solution, which reduces drastically binding to glass. This
procedure was performed before every injection.
Behavioral tests.All of the behavioral procedures were conducted at the
same time of the day (9:00 A.M. to 2:00 P.M.). Motor activity was mon-
itored in four activity cages (Digiscan; AccuScan Instruments, Colum-
bus, OH) in an isolated room for 30 min, immediately after injections at
days 1 or 7 of treatment, or at 2 months after treatment initiation. Hor-
izontal motor activity and number of stereotypies and rearings were
recorded. To determine spatial learning, rats were trained to find a hid-
den platform in a water tank of 150 cm of diameter. Four trials per day
with different start positions, each 30 min apart, were conducted for 5 d
(Mu¨ller et al., 1994), and latency to reach the platform was recorded.
Cutoff time to find the platform was 120 s, and rats failing to find the
platform were placed on it and left there for 15 s. Data acquisition was
performed with a video camera (Noldus Information Technology,
Wageningen, The Netherlands).
Cell cultures and treatments. Primary mixed glial cultures were pre-
pared from neonatal rat cortex as described previously (McCarthy and de
Vellis, 1980). Mechanically dissociated cortices were seeded onto 75 cm 2
flasks in DMEM/Ham’s F-12, supplemented with 10% fetal calf serum
(FCS) and 40 g/ml gentamicine. Cells were cultured in a humified
atmosphere of 5% CO2/95% air at 37°C, and the medium was changed
every 2 or 3 d. After being cultured for 3 weeks, flasks were shaken for 2–3
h at 230 rpm, and floating cells were pelleted, seeded onto a plastic dish,
and incubated at 37°C for 4 h, and loosely bound cells were aspirated.
Adherent cells were detached (PBS plus 1 mM EDTA) and 3  10 4 cells
were seeded onto poly-Orn-coated 96-well plates in DMEM/Ham’s F-12
supplemented with 0.5% FCS. The cultures were at least 99% pure, as
judged by immunocytochemical criteria. Mitochondrial activity (redox
state) was assessed by the MTT assay. Neuron cultures from rat cortices
were prepared as described previously (Ferna´ndez-Tome´ et al., 2004)
with some modifications. Briefly, cerebral cortices were mechanically
dissociated in trypsin (1 mg/ml; Worthington, Freehold, NJ) at 37°C for
10 min, followed by DNaseI addition (50 l; Roche Products, Welwyn
Garden City, UK). Cells were collected after centrifugation and seeded
further in Neurobasal (Invitrogen, San Diego, CA), containing B27 ad-
ditives (Invitrogen), onto gelatin/poly-Lys-coated P24 plates (Falcon,
Franklin Lakes, NJ) at a density of 25 10 4 cells. After 4 d in culture, they
were switched to MEM with N2 additives (Sigma), and treatments (6 d in
vitro) were performed in MEM. Neuron cultures were completely devoid
of microglia as determined by TL or OX42 immunostaining (data not
shown). For cocultures, 15 10 4 microglial cells were seeded in inserts
(membrane pore size, 0.4m; diameter, 9 mm; Costar, Cambridge, MA)
in DMEM containing 0.5% FCS and, at 24 h, were treated withA1– 40 for
4 h to avoid direct toxicity of the peptide on neurons, and the medium
was aspirated and placed over neuron cultures (25 10 4; 24-well plates,
Costar) for an additional 20 h. Drugs were added in 1⁄10 of the final
volume to maintain aggregation of peptides. Cell counts were performed
by Coomassie brilliant blue (0.2% in 10% acetic acid/40% methanol)
staining under phase-contrast microscopy by an observer unaware of the
treatments (four fields per condition in triplicate) in a Zeiss
(Oberkochen, Germany) Axiovert microscope. Neurons showing intact
neurites with uniform diameter and soma with a smooth round appear-
ance were considered viable, whereas neurons with fragmented neurites
and a shrunken cell body were considered nonviable.
TNF- analysis. Cell-free supernatants from microglial cultures were
collected, microfuged, stored at 80°C, and assayed by a TNF- com-
mercial sandwich ELISA (Biosource, Camarillo, CA) in strict accordance
with instructions of the manufacturer. The sensitivity was 10 pg/ml.
Western blot analysis. Western blot was performed as described previ-
ously (Molina-Holgado et al., 2002). Tissues were sonicated in lysis
buffer, samples were centrifuged at high speed for 10 min, and superna-
tants were collected. Total protein was assessed by the Bio-Rad (Hercules,
CA) protein assay. An aliquot of each sample (30 g of protein) was
separated by SDS-PAGE (10%), and proteins were transferred from the
gels onto nitrocellulose membranes. The blots were blocked with 1%
defatted dry milk for 1 h at room temperature and incubated overnight at
4°C with the following antibodies: anti-CB1 (1:5000), anti-CB2 (1:2000),
anti-N-Tyr (1:3000), polyclonal anti-calbindin D-28K (1:5000; Swant,
Bellinzona, Switzerland), and monoclonal anti--tubulin (1:20,000;
Sigma). Finally, samples were subjected to enhanced chemiluminescence
and densitometric analysis. Densitometric analysis of bands was per-
formed by Quantity One quantitation software (version 4.2; Bio-Rad)
from film exposures; the background was always subtracted, and the
percentage of optical density was obtained considering 100% of that of
control samples within the same film. Immunoprecipitations were per-
formed by incubating overnight at 4°C lysate aliquots (100g of protein)
with the anti-N-Tyr antibody (1g/mg protein lysate) prebound to pro-
tein A-agarose (Sigma). After washing, the immunoprecipitates were
resolved by 10% SDS-PAGE and Western blotted with anti-CB1 and
anti-CB2 antibodies as above.
Statistical analysis. Statistical significance analysis was assessed by us-
ing two-way or one-way ANOVA, followed by Bonferroni’s post hoc test
or by unpaired Student’s t test (Prism software, version 4.0; GraphPad
Software, San Diego, CA). A value of p 0.05 was considered significant.
Binding saturation and inhibition curves were plotted by nonlinear re-
gression, and IC50 values were determined using the one-site competi-
tion model (Prism software).
Results
Cannabinoid receptors in AD brain
We studied by immunolabeling the localization of cannabinoid
receptors in relation to senile plaques and microglial activation.
All of the AD cases studied (six of six) showed CB1 and CB2
immunoreactivity in frontal cortical senile plaques (Fig. 1a),
along with markers of microglial activation, such as the histo-
compatibility glycoprotein HLA-DR (McGeer et al., 1987)
(Fig. 1a) and protein nitration (Fig. 1a, N-Tyr). Double-
immunolabeling studies addressed the question of whether CB1
neurons are vulnerable in AD, and microglial activation ac-
counted for it. In agreement with previous immunohistochemi-
cal studies in nonhuman primates (Ong and Mackie, 1999), high
numbers of CB1 neurons and fibers, surrounded by resting mi-
croglia, were observed in all layers of the frontal cortex in controls
(Fig. 1b). CB1-positive neuron density was greatly reduced in AD.
Thus, although in some AD cases (two of six) CB1-positive neu-
rons were still present in areas of microglial activation (Fig. 1b),
they were completely absent in others (four of six) (Fig. 1b).
Likewise, no coexistence of CB1-positive plaques and neurons
was evident in these cases. In addition to CB2 expression in AD
plaques, we also found labeling in tangle-like neurons and dys-
trophic neurites (four of six cases) (Fig. 1c), whereas normal
brain was devoid of any signal (five of five cases). Labeling spec-
ificity was demonstrated by antigenic peptide preabsorption of
the anti-CB antibodies used (Fig. 1c), which completely blocked
immunoreactivity.
AD brain protein nitration (Smith et al., 1996) is thought to be
a consequence of the reaction of NO and superoxide to form the
toxic peroxynitrite radical. In control brain, N-Tyr immunoreac-
tivity was present in astrocytes and in neuronal nuclei (Fig. 2a).
N-Tyr-positive astrocytes were present in AD brain as well (data
not shown), but now many pyramidal neurons showed cytoplas-
mic labeling in all of the cases studied (six of six) (Fig. 2a). Protein
nitration was significantly increased in AD compared with con-
trol brain (Fig. 2b). Moreover, nitration of CB1 and CB2 protein
was markedly increased in AD, as shown by immunoprecipita-
tion studies (Fig. 2c).
Subsequently, we examined the pharmacological characteris-
tics of cannabinoid receptors by using the synthetic cannabinoid
agonist WIN55,212-2. 3H-WIN55,212-2-specific binding, as de-
fined by the selective CB1 antagonist SR141716 (Rinaldi-
Carmona et al., 1994) at 1M, was similar in control and AD cases
(Fig. 3a), as were the saturation curves for the binding process
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(Fig. 3b). Indeed, the density of receptors (Bmax; control, 318.1
87.5 fmol/mg protein; AD, 304.7 62.2 fmol/mg protein; n 3)
and the apparent affinity of the binding (Kd; control, 3.72 0.83
nM; AD, 5.36  0.62 nM; n  3) were unaltered in AD. Indeed,
there was considerable overlap of data points among controls and
AD patients. Although basal 35S-GTPS binding was unchanged
in AD cortex (Fig. 3c), WIN55,212-2-stimulated 35S-GTPS
binding, which measures G-protein coupling and therefore can-
nabinoid receptor activation, was dramatically decreased
(63%) in AD (Fig. 3d). There was no correlation between age,
sex, or postmortem parameters and the values of binding, in
neither controls nor AD patients. Analysis of cannabinoid recep-
tor levels by Western blot showed that CB1 protein expression
was reduced in AD (Fig. 3e), whereas no changes in CB2 expres-
sion were observed (Fig. 3f).
WIN55,212-2 is a mixed CB1/CB2 cannabinoid receptor ago-
nist that activates, with similar affinities, CB1 and CB2 receptors
(Howlett et al., 2002) and may also interact with other, as yet
uncharacterized, receptor subtypes (Breivogel et al., 2001).
Therefore, its pharmacological selectivity was assessed in normal
human brain. 3H-WIN55,212-2 binding was completely dis-
placed by the CB1-selective antagonists SR141716 and AM251
(Lan et al., 1999) (pEC50, 6.88  0.14 and 6.22  0.12, respec-
tively) but was not affected by the selective CB2 antagonist
SR144528 (Rinaldi-Carmona et al., 1998) and the CB2-selective
agonist JWH-133 (Huffman et al., 1999). 35S-GTPS binding
was stimulated by WIN55,212-2 (maximal effect over basal,
87.9 20.2%; pEC50, 6.31 0.05), not affected by JWH-133 (up
to 5 M), and completely blocked by
SR141716 and AM251 (pEC50, 7.87 0.13
and 7.87  0.10, respectively). Together,
these results indicate that, in human brain,
WIN55,212-2 interacts with CB1 or CB1-
like receptors.
Cannabinoid treatment preventsA-
induced toxic effects in vivo
A overexpression or administration to
rodents models AD by activating micro-
glia (Masliah et al., 1996; Frautschy et al.,
1998; Netland et al., 1998) and inducing
cognitive impairment (Mu¨ller et al., 1994;
Delobette et al., 1997). We administered
A (20 g/d, i.c.v) or the control peptide
(SCR) alone or in combination with
WIN55,212-2 (10 g/d) and studied mi-
croglia staining at the end of the treatment
(8 d). Resting microglia were observed in
rats injected with SCR and/or the canna-
binoid (Fig. 4). Interestingly, there was an
intense microglial activation in the cortex
of A-treated rats, which was prevented
by WIN55,212-2 treatment (Fig. 4).
We next examined whether cannabi-
noid administration affected cognitive
function. In contrast to control rats that
learned the spatial navigation task over 5 d
of training, A-treated rats failed to do so.
More important, WIN55,212-2 treatment
prevented A-induced cognitive impair-
ment (Fig. 5a), whereas it did not alter the
learning process when combined with
SCR. This cannabinoid effect was not at-
tributable to changes in the locomotor activity of the animals.
Thus, WIN55,212-2 produced its typical hypolocomotor action
on the first day of treatment, but this effect was not evident at the
seventh day of administration and 2 months later (data not
shown), when the navigation task was performed. As expected,
intracerebroventricular administration of the cannabinoid ago-
nist did not induce adverse effects. Indeed, just after the cessation
of the treatment, the general hematological profiles of the
WIN55,212-2-treated rats were normal. Likewise, neither the
biochemical parameters nor markers for tissue damage changed
at the end of the 7 d administration period.
Interestingly, the changes in neuronal protein expression ob-
served in AD patients were mimicked by repeated administration
of A to rats. Thus, the expression of the neuronal markers cal-
bindin (Fig. 5b,e) and -tubulin (Fig. 5c,f) was significantly re-
duced in both situations. Of importance, this reduction was at-
tenuated by cannabinoid administration to rats (Fig. 5e,f). CB1
expression was also decreased in A-treated rats (Fig. 5d), as was
the case in AD brain (Fig. 3e).
Cannabinoid treatment preventsA-inducedmicroglial
activation and neurotoxicity in vitro
First, we examined the effects of cannabinoids on A-induced
alterations in pure microglial cell cultures. As expected, microglia
in culture expressed both CB1 and CB2 receptors (Walter et al.,
2003) (Fig. 6a). Microglial activation after fibrillar A challenge
(0.5M) included morphological changes at 24 h (Fig. 6b), as well
as increased mitochondrial activity (in the absence of cell prolif-
Figure 1. Cannabinoid receptor localization in AD brain. a, CB1 and CB2 immunostaining in senile plaques, along with the
markers of microglial activation HLA-DR and N-Tyr. b, Double immunostaining of HLA-DR (black, arrows) and CB1 (brown, aster-
isks). CB1-positive neurons in controls (top); CB1-positive neurons are still present (middle) or completely lost (bottom) in areas of
intense microglial activation in AD. c, CB1-positive and CB2-positive neurons and dystrophic neurites in AD. Insets, Absence of
labeling by preabsorption of the antibodies with the antigenic peptide (pep). Scale bars, 25m.
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eration; data not shown) and TNF- release (Meda et al., 1995;
Casal et al., 2002) at 4 h (Fig. 6c) and 24 h (data not shown). The
cannabinoid agonist HU-210 (100 nM), which alone had no sig-
nificant effect on these parameters, counteracted fibrillar A-
induced microglial activation. Indeed, the rod-like morphology
with lamellipodia acquired by fibrillar A-treated cells (Casal et
al., 2002) turned to the resting oval morphology by HU-210 co-
treatment (Fig. 6b). HU-210 also prevented the enhancement in
TNF- release observed after fibrillarA addition. This effect was
mimicked by WIN55,212-2 (100 nM), a cannabinoid devoid of
antioxidant properties (Marsicano et al., 2002), and JWH-133
(100 nM), a CB2-selective agonist (Huffman et al., 1999) devoid of
psychoactive effects when administered in vivo (Sa´nchez et al.,
2001). In summary, cannabinoids counteract A-mediated acti-
vation of microglia in culture.
A exerts direct toxicity on neurons, but indirect neurotoxic-
ity through microglia-mediated activation has been observed as
well (Meda et al., 1995; Tan et al., 2000; Xie et al., 2002). Canna-
binoids were unable to prevent direct toxicity of high concentra-
tions (1–10 M) of A in primary cortical neurons in culture
(data not shown). Subsequently, we assessed indirect A neuro-
toxicity through microglia activation in cocultures. To avoid any
direct toxicity to neurons, microglia seeded in inserts was treated
with the peptides or the cannabinoids for 4 h, a time sufficient for
microglia activation. Indeed, there was significant neurotoxicity
when neurons were exposed for 20 h to microglial cells pretreated
with 0.5 M fibrillar A for 4 h (Fig. 7a,b), whereas, at this time
point and concentration, the peptide did not significantly alter
neuron survival in the absence of microglial cells (Fig. 7a) (Barger
et al., 1995; Ferna´ndez-Tome´ et al., 2004). Both WIN55,212-2
and JWH-133 (100 nM) prevented microglia-mediated neuro-
toxicity afterA treatment (Fig. 7a,b). The neuroprotective effect
of WIN55,212-2 on A neurotoxicity in cocultures was pre-
vented by the selective antagonists SR141716 and SR144528,
whereas the effect of JWH-133 was only counteracted by the latter
(Fig. 7a). These results support that the neuroprotective effect of
cannabinoids relies on the prevention of A-induced microglial
activation.
Discussion
One of the key features of AD is microglial activation, a process
that may serve dual functions. For a long time, it was thought to
be responsible for the ongoing inflammatory process occurring
in the neurological condition (for review, see Akiyama et al.,
2000). However, it has been recognized recently that removal of
A by activated microglia may be beneficial (Bard et al., 2000;
Wyss-Coray et al., 2001; Jantzen et al., 2002). These cells are part
of the senile plaques in cerebral cortex and hippocampus of the
afflicted patients. We have shown that CB1 and CB2 receptors are
colocalized in plaques, in line with a recent report (Benito et al.,
2003). Upregulation of inducible nitric oxide synthase occurs in
senile plaques in AD (Lee et al., 1999) and in microglia after A
administration in vivo (Weldon et al., 1998). Furthermore, N-Tyr
immunoreactivity has been observed in plaques in AD (Vodovotz
et al., 1996) and in mice carrying amyloid precursor protein plus
presenilin-1 mutations (Matsuoka et al., 2001). Protein nitration
therefore appears to be a marker of the effects of the peroxynitrite
radical and a consequence of microglial activation. In normal
human brain, we observed a high density of CB1-positive neurons
(Ong and Mackie, 1999; Benito et al., 2003), mostly pyramidal
cells, which are lost in AD brain, in particular in areas bearing
plaques, pointing to the vulnerability of such neurons to the toxic
species generated by microglia (e.g., NO and cytokines). Given
that CB-positive neurons were segregated from plaques, their
possible contribution to CB receptors in plaques may be ruled
out, and this points to microglial cells as the unique source.
Previous works in human brain have mapped CB receptors by
autoradiographic techniques (Westlake et al., 1994; Glass et al.,
1997, 2000), but their pharmacological characteristics were not
determined. Furthermore, it is widely accepted that CB2 recep-
tors are not present in normal brain, but we wondered whether,
by using an appropriate selection of cold ligands to define specific
binding, we would be able to show CB2 receptors, at least in
pathological brain, such as AD. In human cortical membranes,
3H-WIN55,212-2 binding to CB1 receptors, as defined by the
CB1-selective antagonist SR141716, was saturable and of high
affinity. The apparent affinity is similar to that observed in rat
brain (Breivogel et al., 1997), albeit the density of binding sites
(Bmax) is much lower. Rather than a species trait, aging (Mailleux
and Vanderhaeghen, 1992; Romero et al., 1998; Mato and Pazos,
2004) may account for the difference in density, given that our
controls were nonpathological aged subjects. WIN55,212-2 is a
mixed CB1/CB2 cannabinoid receptor agonist that activates, with
similar affinities, CB1 and CB2 receptors (Howlett et al., 2002)
and may also interact with other, as yet uncharacterized, receptor
subtypes (Breivogel et al., 2001). The relative potencies of the
drugs in our pharmacological studies are in general agreement
with previous studies (Rinaldi-Carmona et al., 1994, 1998;
Figure 2. Nitration of CB1 and CB2 is increased in AD brain. a, N-Tyr-immunoreactive astro-
cytes in control (top); nuclear N-Tyr expression in control (middle); cytoplasmic N-Tyr expres-
sion in AD (arrows, bottom). Scale bar, 25m. b, Total protein nitration (as detected byWest-
ern blot) in control (C) and AD brain. OD, Optical density. c, Lysates from control and AD brains
were immunoprecipitated with anti-N-Tyr antibody and blotted with anti-CB1 or CB2 antibod-
ies. The percentage of nitration of total CBs is shown. b, c, Results are mean SEM of n 18
in each group; **p 0.01 and ***p 0.001 comparedwith controls (Student’s t test); repre-
sentative blots are shown. Error bars represent SEM.
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Breivogel et al., 1997), including those in cells transfected with
the cloned human cannabinoid receptors (Felder et al., 1995;
MacLennan et al., 1998). Together, these results indicate that, in
human brain, WIN55,212-2 interacts with CB1 or CB1-like recep-
tors. CB1 receptors outnumber other characterized cannabinoid
receptors, and such a high density may have masked CB2 recep-
tors, which were observed by immunohistochemistry, with a very
restricted localization in AD brain.
In a previous work, cannabinoid receptor binding in cortical
areas of AD brain was unchanged, and the reduction in hip-
pocampal subfields was unrelated to the pathological changes
(Westlake et al., 1994). However, in agreement with our histolog-
ical findings, in biochemical studies, we have shown that CB1
protein expression and function are markedly reduced in AD.
Indeed G-protein coupling, as judged by 35S-GTPS binding,
was greatly diminished in samples from
AD patients. Given that enhanced protein
nitration was observed along CB receptors
in plaques, we examined whether they
may be a target for such alteration. In AD,
total protein nitration is increased com-
pared with controls (Aoyama et al., 2000).
More specifically, both CB1 and CB2 re-
ceptor proteins show enhanced protein
nitration in AD than in controls. It should
be noted that protein nitration, known to
inactivate other proteins in AD (Aoyama
et al., 2000), might interfere with CB re-
ceptor function as well. In summary, sig-
nificant alterations in the localization, ex-
pression, and function of cannabinoid
receptors occur in AD and may play a role
in its physiopathology.
Our present results confirm and ex-
tend those of previous works, showing
marked alterations in cannabinoid re-
ceptors in AD brain. Benito et al. (2003)
reported that CB1-positive neurons ap-
peared to be preserved in AD parahip-
pocampal cortex, but frontal cortex was
not studied. Therefore, the region of study
may account for the difference between their and our results.
Autoradiographic studies, used by Westlake et al. (1994), lack
cellular resolution, which may explain why decreased binding did
not correlate with areas showing pathology (senile plaques and
tangles) in hippocampal subfields in AD. In this work, we com-
bined histological, pharmacological, and biochemical techniques
to show loss of CB1-positive neurons in frontal cortex of AD
brain, as well as decreased CB1 protein expression and G-protein
coupling, despite preserved binding.
In the present study, we used rats repeatedly injected intrac-
erebroventricularly with A to model AD. Indeed, we reported
decreased muscarinic receptors in cortex (Pavı´a et al., 2000) and
increased monomeric G1 acetylcholinesterase isoform (Sa´ez-
Valero et al., 2002), similar to those in AD. These animals show
increased microglial reaction at the end of A administration
(Netland et al., 1998; Weldon et al., 1998) and cognitive impair-
ment at 2 months (Delobette et al., 1997) compared with control
animals. Interestingly, A-treated rats reproduced the same re-
duction in neuronal markers, including CB1 protein, occurring in
AD, validating further the experimental model. Cannabinoids
induce neuroprotection against excitotoxicity (Shen and Thayer,
1998), ischemia (Nagayama et al., 1999), and glucose deprivation
(Nagayama et al., 1999) in vitro. These compounds are also effec-
tive against acute brain damage in vivo, including excitotoxic
insult (van der Stelt et al., 2001), ischemia (Nagayama et al.,
1999), and acute brain trauma (Panikashvili et al., 2001). Fur-
thermore, the involvement of CB1 receptors and their endoge-
nous ligands as neuroprotectants has been demonstrated recently
in CB1-null mutants, which are more susceptible to neurodegen-
eration (Parmentier-Batteur et al., 2002; Marsicano et al., 2003).
In this work, we report that microglial activation induced in vivo
by A was completely prevented by cannabinoid administration.
We have shown that the loss of neuronal markers induced by A
is attenuated by cannabinoid administration. More importantly,
the cognitive deficits occurring in A-treated rats are also pre-
vented by the cannabinoid. Together, these results constitute the
Figure 3. CB1 receptor binding is unaltered and G-protein coupling is reduced in AD frontal cortex.a, Specific
3H-WIN55,212-2
(WIN)binding (n18 ineachgroup).b, Representative 3H-WIN55212-2binding saturation curves (n3 ineachgroup). c, Basal
35S-GTPS binding (n 18 in each group). d, WIN55,212-2-stimulated 35S-GTPS binding (n 18; *p 0.05 compared with
controls; Student’s t test). e, f, CB1 (e) and CB2 (f ) expression (as detected by Western blot) in control and AD brain. OD, Optical
density. Results are mean SEM of n 18 in each group; *p 0.05 compared with controls (Student’s t test); representative
blots are shown. Error bars represent SEM.
Figure4. Cannabinoid treatmentpreventsA-inducedmicroglial activation in rats. Tomato
lectin binding to microglial cells in frontal cortex of rats 24 h after treatment completion was
increased by A compared with SCR peptide and prevented by WIN55,212-2 (WIN) cotreat-
ment; pictures of one representative animal of three per group are shown. Initial magnification
was 200.
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first evidence that cannabinoids exert
neuroprotection in a model of AD.
Cannabinoids prevent microglial acti-
vation and decrease NO production
(Waksman et al., 1999) and TNF- ex-
pression and release (Puffenbarger et al.,
2000; Facchinetti et al., 2003) evoked by
different agents. In this work, cannabi-
noids with different pharmacological pro-
files effectively counteracted the well
known A-induced microglial activation,
in particular TNF- release, which is po-
tentially neurotoxic. Milton (2002) re-
ported that the toxicity of high concentra-
tions (25 M) of A peptides was
prevented by endocannabinoids in NT-2
cells, a human teratocarcinoma cell line
that can be differentiated into neuronal
phenotype, and in myeloma cells. Thus,
anandamide and noladin ether protected
the cells by a CB1- or a CB1/CB2-mediated
effect, respectively, depending on the cell
line used. These results were not repro-
duced in our neuronal cultures. Thus, dif-
ferent synthetic cannabinoids did not pre-
vent direct toxicity of A on primary
neurons in culture. However, a neuropro-
tective effect of cannabinoids was dis-
closed using a A microglia-mediated
neurotoxicity paradigm. The selective CB2
agonist JWH-133 was as effective as
WIN55,212-2, the mixed CB1/CB2 ago-
nist. As shown in microglia–neuron co-
cultures and in A-treated rats, these ben-
eficial effects of cannabinoids may rely on
their ability to block A-induced micro-
glial activation. In line with this notion,
cannabinoids are unable to prevent A-
induced death of primary neurons in cul-
ture. This may be of particular importance
for the possible endorsement of cannabi-
noids to therapeutic applications because
of their psychotropic side effects, which
may cast clinical concern. CB2 receptors
appear to be exclusively expressed by mi-
croglia, and blockade of its activation may
be attained by CB2 agonists with no overt
psychoactivity.
The search for new and effective treat-
ments for AD is of crucial importance, and
limiting ongoing inflammatory responses
secondary to microglial activation has
been proposed (Akiyama et al., 2000).
Furthermore, recent studies on therapeu-
tic strategies for neurodegenerative dis-
eases such as Parkinson’s disease and AD
have focused on the neuroprotective
properties (e.g., slowing the ongoing neu-
rodegeneration) rather than just on palli-
ating symptoms of the diseases (Dawson
and Dawson, 2002). Because cannabi-
noids combine both anti-inflammatory
and neuroprotective actions, our findings
Figure 6. Cannabinoids prevent A-induced microglial activation in vitro. a, Immunostaining of cultured microglia with
anti-OX42 (top), CB1 (middle), and CB2 (bottom) antibodies. b, Fibrillar A1–40 (fib), but not soluble A1–40 (sol), induced a
rod-like morphology, which was prevented by HU-210 (HU). c, Cannabinoids [HU-210 (HU), WIN55,212-2 (WIN), and JWH-133
(JWH), at 100 nM for 4 h] prevented TNF- release and mitochondrial activity, as induced by fibrillar A1–40 (500 nM). TNF-
release in controls was 26.1 4.5 pg/ml. Results are mean SEM of n 4–6; *p 0.05 and **p 0.01 compared with
solubleA1–40-treated control cultures;
#p 0.05, ##p 0.01 compared with fibrillarA1–40-treated cultures (ANOVA with
Bonferroni’s post hoc test).
Figure 5. Cannabinoid treatment prevents cognitive impairment and loss of neuronal markers in rats. a, Latency (in seconds)
to find a hidden platform in thewatermaze during training. Results aremean of n 5 in each group; SEM have been omitted for
clarity andwere always12%of themean; *p 0.05 and **p 0.01 comparedwith SCR-treated rats at the same training day;
#p 0.05 and ##p 0.01 compared with A-treated rats (ANOVA with Bonferroni’s post hoc test). WIN, WIN55,212-2. b, c,
Expression of calbindin (b) and-tubulin (c) in control (C) and AD frontal cortex; results are mean SEM of n 18 control and
AD; ***p 0.001 compared with controls. d–f, Expression of CB1 (d), calbindin (e), and-tubulin (f ) in frontal cortex of rats at
2 months after treatment. OD, Optical density. Results are mean SEM of n 5 in each group; *p 0.05 and **p 0.01
comparedwithSCR-treated rats (ANOVAwithBonferroni’spost hoc test); representativeblots are shown. Error bars represent SEM.
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may set the basis for the use of these compounds as a therapeutic
approach for AD.
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